Mantle Cell Lymphoma

Cirmtuzumab Added to Ibrutinib Induces Responses in R/R MCL and CLL

June 06, 2020

Compelling objective responses and safety results were demonstrated with the combination of cirmtuzumab and ibrutinib in cohorts of patients with mantle cell lymphoma and chronic lymphocytic leukemia, who were treated in the phase 1b/2 clinical trial.

KTE-X19 Appears Tolerable in Relapsed/Refractory Mantle Cell Lymphoma

May 30, 2020

The autologous anti-CD19 CAR T-cell therapy KTE-X19 had a pharmacodynamic profile associated with efficacy and treatment-related neurological events in patients with relapsed/refractory mantle cell lymphoma, according to data from the ZUMA-2 clinical trial.

Venetoclax May Play Role as Salvage Therapy in Multiply Relapsed MCL

May 12, 2020

“Our study demonstrates that venetoclax is a potential salvage therapy in multiply relapsed patients with MCL. The majority (92%) patients in this study were exposed to BTKi, 66% were BTKi refractory, and these patients exhibited poor outcomes."

BTK Inhibitors Improve Responses Relapsed/Refractory Mantle Cell Lymphoma

May 11, 2020

Andre Goy, MD, discusses the different BTK inhibitors as treatment of patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib Plus Venetoclax Induced Improved Immunity in R/R Mantle Cell Lymphoma

May 08, 2020

In an interview with Targeted Oncology, David Ritchie, MD, PhD, discussed the findings from the substudy of the AIM clinical trial, which evaluated the combination of venetoclax and ibrutinib in patients with MCL.

Efficacy of Obinutuzumab Plus Venetoclax in Ibrutinib-Resistant MCL Observed in the Community Setting

May 06, 2020

“To the best of our knowledge, this is the first report about obinutuzumab and venetoclax induced CR in a rituximab-intolerant patient with an ibrutinib-resistant leukemic MCL."

Exploring Subsets of Patients With Mantle Cell Lymphoma

April 20, 2020

Sonali M. Smith, MD, discusses the current understanding of mantle cell lymphoma and how this understanding has evolved over recent years to understand different subsets of the disease that may require different frontline treatment for patients.

R-BAC Can Potentially Bridge Later-line Therapy in R/R Mantle Cell Lymphoma

April 15, 2020

A high response rate was demonstrated with the rituximab, bendamustine, and cytarabine regimen as treatment of patients with relapsed or refractory mantle cell lymphoma following treatment with a Bruton tyrosine kinase inhibitor, hinting that the regimen may be an effective bridge to allogeneic stem cell transplantation in patients who are transplant eligible, according to data from a retrospective cohort study.

Bortezomib Maintenance Fails to Improve Transplant Outcomes in Newly Diagnosed Mantle Cell Lymphoma

April 14, 2020

Bortezomib as maintenance therapy following autologous stem cell transplant did not demonstrate a positive effect as treatment of young newly diagnosed patients with mantle cell lymphoma, according to the results of the phase II HOVON trial.

Options for Treating Relapsed/Refractory Follicular Lymphoma

April 03, 2020

Sonali M. Smith, MD, discusses how to handle patients with follicular lymphoma when they relapse, especially if they are early progressors.